Drugs / MT200605
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05948774 | Jul 2023 → Jan 2024 | — | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07205328 | Oct 2025 → May 2026 overdue | ischemic stroke | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT200605 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07205328 ↗ |
| Action | Activate | “tyrosine kinase B (TrkB) receptor agonist” NCT05948774 ↗ |
| Modality | Small molecule | “novel investigational synthetic small molecule tyrosine kinase B (TrkB) receptor agonist” NCT05948774 ↗ |
| Route | Intravenous | “MT200605 will single Intravenous (IV) infusion for 1h” NCT05948774 ↗ |